Literature DB >> 7737765

Trivial or terrible? The psychosocial impact of psoriasis.

R G Fried1, S Friedman, C Paradis, M Hatch, Y Lynfield, C Duncanson, A Shalita.   

Abstract

BACKGROUND: Psoriasis remains a chronic disease with lesions that are often extensive and disfiguring. While the potential for psychosocial morbidity and impairment are recognized, the literature remains equivocal with regard to the prevalence and degree of this impairment.
METHODS: The present study utilized a new questionnaire designed to assess the type and degree of psychosocial impairment present among psoriasis patients. The questionnaire was designed to assess major areas of psychosocial functioning and was completed by 64 patients undergoing outpatient treatment.
RESULTS: Approximately half the patients were found to have moderate to extreme levels of anxiety, depression, and anger. Patients reported experiencing these negative emotional sequelae both during their disease flares and during periods of remission. Patients were also found to have moderate to extreme levels of pruritus associated with their flares. Psychologic morbidity was positively associated with length of disease flare. Significant levels of social embarrassment, life disruption, and social withdrawal were found as well.
CONCLUSIONS: Psoriasis does appear to cause significant psychosocial morbidity. Greater awareness by physicians and more comprehensive treatment addressing these psychosocial components may avert, or at least minimize, some of these negative sequelae.

Entities:  

Mesh:

Year:  1995        PMID: 7737765     DOI: 10.1111/j.1365-4362.1995.tb03588.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  13 in total

1.  Sleep Quality and its Association with Disease Severity in Psoriasis.

Authors:  Mehmet Melikoglu
Journal:  Eurasian J Med       Date:  2017-06

2.  Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life.

Authors:  Young Wook Lee; Eun Joo Park; In Ho Kwon; Kwang Ho Kim; Kwang Joong Kim
Journal:  Ann Dermatol       Date:  2010-11-05       Impact factor: 1.444

3.  The relationship between demographic and clinical variables, and quality of life aspects in patients with psoriasis.

Authors:  A Wahl; T Moum; B R Hanestad; I Wiklund
Journal:  Qual Life Res       Date:  1999-06       Impact factor: 4.147

4.  Impact of depressive symptoms on oxidative stress in patients with psoriasis.

Authors:  Fatih Karababa; Yavuz Yesilova; Enver Turan; Salih Selek; Hacer Altun; Sahabettin Selek
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

5.  Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Authors:  Richard G B Langley; Kristian Reich; Vibeke Strand; Steven R Feldman; Carle Paul; Kenneth Gordon; Richard B Warren; Darryl Toth; Enkeleida Nikaï; Baojin Zhu; Orin Goldblum; Emily Edson-Heredia; Hilde Carlier; Russel Burge; Chen-Yen Lin; Kristin Hollister; Matthias Augustin
Journal:  Qual Life Res       Date:  2019-10-26       Impact factor: 4.147

6.  Biologics in the management of psoriasis.

Authors:  Jennifer D Bahner; Lauren Y Cao; Neil J Korman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-07-23

7.  Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

Authors:  Jean-Paul Ortonne; Neil Shear; Stephen Shumack; Eric Henninger
Journal:  BMC Dermatol       Date:  2005-12-16

8.  Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.

Authors:  Georgia Avgerinou; Ioannis Bassukas; Georgios Chaidemenos; Andreas Katsampas; Marita Kosmadaki; Hara Kousoulakou; Athanasios Petridis; Brad Schenkel; Dimitrios Sotiriadis; Theofanis Spiliopoulos; Panagiotis Stavropoulos; Evgenia Toumpi; Loukas Xaplanteris
Journal:  BMC Dermatol       Date:  2012-07-25

9.  'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis.

Authors:  Pauline A Nelson; Zoë Barker; Christopher E M Griffiths; Lis Cordingley; Carolyn A Chew-Graham
Journal:  BMC Fam Pract       Date:  2013-10-20       Impact factor: 2.497

10.  Illness acceptance degree versus intensity of psychopathological symptoms in patients with psoriasis.

Authors:  Magdalena Kostyła; Klaudia Tabała; Józef Kocur
Journal:  Postepy Dermatol Alergol       Date:  2013-06-20       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.